Human amniotic fluid stem cells suppress PBMC proliferation through IDO and IL-10-dependent pathways

Current Stem Cell Research and Therapy

Volumn 9, Issue 1, 2014, Pages 36-45

  Luo, Chengfeng ^a   Jia, Wenwen ^a,b   Wang, Kai ^a   Chi, Fengli ^a   Gu, Yanqiong ^a   Yan, Xiaoling ^a   Zou, Gang ^a   Duan, Tao ^a   Zhou, Qian ^a  

^a Shanghai First Maternity and Infant Health Hospital   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

Human amniotic fluid stem cells; Il 10; Immunosuppression; Indoleamine 2,3 dioxygenase; Peripheral blood mononuclear cells

Indexed keywords

AMNIOTIC FLUID; ANTIGENS, CD; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; EMBRYONIC STEM CELLS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR;

EID: 84904500799     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X113086660067     Document Type: Article

References (56)

1. Phermthai, T, Odglun Y, Julavijitphong S, et al. A novel method to derive amniotic fluid stem cells for therapeutic purposes. BMC Cell Biol 2010; 11: 79.
2. Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod 2004; 19: 1450-6.
3. De Coppi P, Bartsch GJ, Siddiqui MM, et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007; 25: 100-6.
4. Bossolasco P, Montemurro T, Cova L, et al. Molecular and pheno-typic characterization of human amniotic fluid cells and their differentiation potential. Cell Res 2006; 16: 329-36.
5. Tsai MS, Hwang SM, Tsai YL, Cheng FC, Lee JL, Chang YJ. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod 2006;74: 545-51.
6. Liang F, Wang YF, Nan X, et al. [In vitro differentiation of human bone marrow-derived mesenchymal stem cells into blood vessel endothelial cells]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005; 27: 665-9.
7. Rosner M, Schipany K, Gundacker C, et al. Renal differentiation of amniotic fluid stem cells: perspectives for clinical application and for studies on specific human genetic diseases. Eur J Clin Invest 2012; 42: 677-84.
8. Siegel N, Valli A, Fuchs C, Rosner M, Hengstschlager M. Induction of mesenchymal/epithelial marker expression in human amniotic fluid stem cells. Reprod Biomed Online 2009; 19: 838-46.
9. Mirabella T, Poggi A, Scaranari M, et al. Recruitment of host's progenitor cells to sites of human amniotic fluid stem cells implantation. Biomaterials 2011; 32: 4218-27.
10. Moorefield EC, McKee EE, Solchaga L, et al. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. PLoS One 2011; 6: e26535.
11. Yeh YC, Lee WY, Yu CL, et al. Cardiac repair with injectable cell sheet fragments of human amniotic fluid stem cells in an immunesuppressed rat model. Biomaterials 2010; 31: 6444-53.
12. Kim SW, Zhang HZ, Guo L, Kim JM, Kim MH. Amniotic mesen-chymal stem cells enhance wound healing in diabetic NOD/SCID mice through high angiogenic and engraftment capabilities. PLoS One 2012; 7: e41105.
13. Santana AC, Delle H, Cavaglieri RC, et al. Protective effects of human amniotic fluid stem cells in a model of aorta allograft vasculopathy in rats. Transplant Proc 2012; 44: 2490-4.
14. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSCderived prostaglandin E2. Blood 2009; 113: 6576-83.
15. Kronsteiner B, Peterbauer-Scherb A, Grillari-Voglauer R, et al. Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol 2011; 267: 30-38.
16. Comoli P, Ginevri F, Maccario R, et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23: 1196-202.
17. Najar M, Raicevic G, Boufker HI, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010; 264: 171-9.
18. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-33.
19. Maccario R, Podesta M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516-25.
20. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce Tcell unresponsiveness. Blood 2005; 105: 2214-19.
21. Antony PA, Paulos CM, Ahmadzadeh M, et al. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol 2006; 176: 5255-66.
22. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-32.
23. Xiao Q, Wang SK, Tian H, et al. TNF-alpha increases bone marrow mesenchymal stem cell migration to ischemic tissues. Cell Biochem Biophys 2012; 62: 409-14.
24. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-43.
25. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Ramesh-war P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGFbeta. J Immunol 2010; 184: 5885-94.
26. Rizzo R, Campioni D, Stignani M, et al. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 2008; 10: 364-75.
27. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
28. Hegyi B, Kudlik G, Monostori E, Uher F. Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. Biochem Biophys Res Commun 2012; 419: 215-20.
29. Francois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012; 20: 187-95.
30. Sabat R, Grutz G, Warszawska K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331-44.
31. Morel AS, Quaratino S, Douek DC, Londei M. Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: definition of a maturative step. Eur J Immunol 1997; 27: 26-34.
32. Yang S, Li W, Liu W, et al. IL-10 gene modified dendritic cells induced antigen-specific tolerance in experimental autoimmune myocarditis. Clin Immunol 2006; 121: 63-73.
33. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867-70.
34. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-21.
35. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-74.
36. Mellor AL, Sivakumar J, Chandler P, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001; 2: 64-8.
37. von Rango U, Krusche CA, Beier HM, Classen-Linke I. In-doleamine-dioxygenase is expressed in human decidua at the time maternal tolerance is established. J Reprod Immunol 2007; 74: 34-45.
38. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol 2007; 39: 2167-72.
39. Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol 2008; 253: 16-22.
40. Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41.
41. Thrasher AJ. New insights into the biology of Wiskott-Aldrich syndrome (WAS). Hematology Am Soc Hematol Educ Program 2009: 132-8.
42. Krauss AC, Kamani NR. Hematopoietic stem cell transplantation for pediatric autoimmune disease: where we stand and where we need to go. Bone Marrow Transplant 2009; 44: 137-43.
43. Mattson MR. Graft-versus-host disease: review and nursing implications. Clin J Oncol Nurs 2007; 11: 325-8.
44. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005; 23: 845-56.
45. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008; 451: 937-42.
46. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of anti-tumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006; 177: 896-904.
47. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
48. Chaves AC, Ceravolo IP, Gomes JA, Zani CL, Romanha AJ, Gazzinelli RT. IL-4 and IL-13 regulate the induction of indoleamine 2,3-dioxygenase activity and the control of Toxoplasma gondii replication in human fibroblasts activated with IFN-gamma. Eur J Immunol 2001; 31: 333-44.
49. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47-57.
50. Silva JS, Morrissey PJ, Grabstein KH, Mohler KM, Anderson D, Reed SG. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med 1992; 175: 169-74.
51. Gazzinelli RT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J Immunol 1992; 148: 1792-6.
52. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041-8.
53. Terness P, Bauer TM, Rose L, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002; 196: 447-57.
54. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest 2004; 114: 1209-17.
55. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149: 353-63.
56. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-62.